Alumis Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

Alumis (Nasdaq: ALMS) announced on January 6, 2026 its plan to commence an underwritten public offering of $175.0 million of common stock, with Alumis as the seller.

The company also expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares. The offering is subject to market and other conditions and may not be completed.

Joint book-running managers for the proposed offering are Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities. A preliminary prospectus supplement will be filed with the SEC and be available on sec.gov.

Positive

• Proposed gross proceeds of $175.0 million
• Underwriters' option available: up to $26.25 million

Negative

• Potential equity dilution for existing shareholders from the offering
• Offering is subject to market and other conditions; completion not assured

News Market Reaction

+95.31% 7.0x vol

37 alerts

+95.31% News Effect

+106.7% Peak in 5 hr 22 min

+$943M Valuation Impact

$1.93B Market Cap

7.0x Rel. Volume

On the day this news was published, ALMS gained 95.31%, reflecting a significant positive market reaction. Argus tracked a peak move of +106.7% during that session. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $943M to the company's valuation, bringing the market cap to $1.93B at that time. Trading volume was exceptionally heavy at 7.0x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Proposed offering size: $175.0 million Underwriters’ option: $26.25 million Current share price: $8.31 +5 more

8 metrics

Proposed offering size $175.0 million Underwritten public offering of common stock

Underwriters’ option $26.25 million 30-day option for additional common shares

Current share price $8.31 Pre-offering market price from context data

Price change 24h -7.2% Move on day of offering announcement

Today’s volume 1,837,814 shares Trading volume on offering announcement day

Volume vs 20-day avg 1.49x Relative to 20-day average volume

52-week high $12.4398 Pre-offering 52-week high level

52-week low $2.7601 Pre-offering 52-week low level

Market Reality Check

Price: $24.34 Vol: Volume 1,837,814 is 1.49x...

normal vol

$24.34 Last Close

Volume Volume 1,837,814 is 1.49x the 20-day average, showing elevated trading ahead of the offering. normal

Technical Price at $8.31 is trading above the $5.28 200-day moving average despite the announced equity raise.

Peers on Argus

ALMS declined 7.2% while close biotech peers showed smaller mixed moves (e.g., C...

ALMS declined 7.2% while close biotech peers showed smaller mixed moves (e.g., CRVS -6.34%, ERAS -2.24%, PRTA -1.52%, ATXS -0.31%, ITOS +0.10%), indicating a company-specific reaction to the offering.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Data call preview	Neutral	-7.2%	Announcement of conference call to discuss upcoming Phase 3 ONWARD topline data.
Nov 13	Earnings update	Neutral	+0.8%	Q3 2025 results and funding runway into 2027 with ongoing clinical milestones.
Nov 04	Investor conferences	Neutral	-0.2%	Participation in November 2025 healthcare investor conferences and webcasts.
Aug 29	Investor conferences	Neutral	-1.3%	Announcement of six September 2025 investor conference appearances with webcasts.
Aug 13	Earnings and merger	Positive	-0.7%	Q2 2025 results, completion of ACELYRIN merger and strong cash position disclosure.

Pattern Detected

Shares often show modest moves around conferences and earnings, with occasional negative divergence on seemingly neutral or positive corporate updates.

Recent Company History

Over the last several months, Alumis has focused on advancing late-stage programs and communicating financial progress. Earnings reports in August 2025 and November 2025 highlighted substantial cash resources and the ACELYRIN merger, while multiple conference participations in August and November 2025 kept investors updated on the story. A January 2026 event previewed Phase 3 ONWARD topline data. Today’s proposed common stock offering follows this period of active clinical and investor communication, adding a capital-raising element to the trajectory.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-03

The company has an active Form S-3 shelf registration filed on 2025-07-03 with no recorded usage in recent 424B filings, providing a framework for offerings like this one.

Market Pulse Summary

The stock surged +95.3% in the session following this news. A strong positive reaction would align w...

Analysis

The stock surged +95.3% in the session following this news. A strong positive reaction would align with the company’s established funding needs and late-stage pipeline but would contrast with today’s -7.2% move seen in the context data. Historically, ALMS has shown mixed alignment between news tone and price, with both aligned and divergent reactions. Investors would have needed to weigh the implications of an equity raise against prior cash disclosures and the existing S-3 shelf capacity when assessing sustainability.

Key Terms

underwritten public offering, shelf registration statement, form s-3, base prospectus, +2 more

6 terms

underwritten public offering financial

"announced its plans to commence an underwritten public offering of $175.0 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

base prospectus regulatory

"on Form S-3, including a base prospectus, that was previously filed"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

preliminary prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering"

A preliminary prospectus supplement is an initial document that provides important details about a new stock or bond offering before it is finalized. It helps investors understand what is being sold and why, so they can decide whether to invest. Think of it as a preview before the full sales brochure is ready.

prospectus regulatory

"preliminary prospectus supplement and accompanying prospectus relating to the proposed offering"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. All of the shares are being offered by Alumis. In addition, Alumis expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock at the public offering price per share. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on August 19, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained, when available from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com; or Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Alumis

Alumis is a clinical-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib (or envu, formerly known as ESK-001) for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Alumis Contact Information 
Teri Dahlman 
Red House Communications 
teri@redhousecomms.com

FAQ

What size offering did Alumis (ALMS) announce on January 6, 2026?

Alumis announced a proposed underwritten offering of $175.0 million of common stock.

Does the Alumis (ALMS) offering include an option for additional shares?

Yes — there is a 30-day underwriters' option to purchase up to an additional $26.25 million of shares.

Are the shares in the Alumis (ALMS) offering being sold by the company or insiders?

All of the shares in the proposed offering are being offered by Alumis (the company).

Who are the lead underwriters for Alumis (ALMS) public offering?

Joint book-running managers are Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities.

Where can investors find the Alumis (ALMS) preliminary prospectus supplement?

The preliminary prospectus supplement will be filed with the SEC and is available for free on sec.gov when posted.

What does the Alumis (ALMS) announcement mean for existing shareholders?

The proposed offering may result in equity dilution for existing shareholders if completed.